Read the 4th quarter, 2000 Newsletter and recent scientific references CBF Lesioning in Rabbits / by Beach T / featuring ME20.4-SAP, Cat. #IT-15 Chronic Pain Therapeutic NIDA funds ATS research on Galanin Targeting Talk: Second Immunotoxins Targeting Tools: New Products Mouse-Specific p75 Immunotoxin (Cat. #IT-16) ME20.4 Monoclonal and Immunotoxin (Cat. #IT-15, Cat. #AB-N07)
Targeting Trends 2000 Newsletter Read More »
The ME20.4 monoclonal antibody (Cat. #AB-N07) was derived from immunization of mice with WM245 melanoma cells. The antibody can be used in Western blot, immunoprecipitation, immunohistochemistry, FACS analysis, and electron microscopy. The known species reactivity includes human, primate, rabbit, raccoon, dog, cat, and sheep. The ME20.4-SAP immunotoxin (Cat. #IT-15) is a chemical conjugation between the
Targeting Tools: ME20.4 Monoclonal and Immunotoxin Read More »
The long-sought mouse cholinergic toxin has been found! The mouse cholinergic immunotoxin (Cat. #IT-16) is being released for sale at the Society for Neuroscience meeting in New Orleans, November 4-9, 2000! For years ATS has received requests for a molecule that would eliminate cholinergic neurons in the basal forebrain of mice in a manner that
Targeting Tools: Mouse-Specific p75 Immunotoxin Read More »
In April of this year ATS applied for funding from National Institute for Mental Health (NIMH) for the toxicology studies of Substance P-Saporin (SP-SAP). This $674,000 supplement to a previous NIMH Small Business Innovative Research grant will cover one of the FDA-required safety and toxicology studies and will bring us closer to clinical trials in
Chronic Pain Therapeutic Read More »
Advanced Targeting Systems (ATS) has just been awarded a $100,000 research grant from the National Institute on Drug Abuse (NIDA). This Phase I SBIR (Small Business Innovation Research) grant proposes to develop a research reagent to study the function of the neuropeptide, galanin. This will be an important tool for scientists to use in the
NIDA funds ATS research on Galanin Read More »
Contributed by Dr. Thomas Beach, Sun Health Research Institute, Sun City, AZ Our hypothesis, developed through our own human and animal studies1-6 and the cell culture work of others (beginning with Nitsch7), is that the normal, age-related loss of cortical cholinergic innervation leads to Aβ deposition and Alzheimer’s disease. To test this hypothesis, we have been
Cover Article: CBF Lesioning in Rabbits Read More »
ADVANCED TARGETING SYSTEMS ANNOUNCES ITS MOLECULAR NEUROSURGERY TECHNOLOGY OPENS DOOR TO PERMANENT RELIEF FOR CHRONIC PAIN SAN DIEGO, CA, NOVEMBER 18, 1999— Chronic, intractable pain afflicts millions of Americans. Pioneering new technology, called molecular neurosurgery and developed by Advanced Targeting Systems, a San Diego-based company, provides the springboard for a one-time injection of a targeted
SP-SAP as Chronic Pain Therapeutic Read More »
Awarded by ATS at Society for Neuroscience (SFN) Miami, Florida • October 23-28, 1999 474.6 Abolition of cyanide-induced sympathoexcitation by selective lesion of bulbospinal catecholaminergic neurons. A.M. SCHREIHOFER* and P.G. GUYENET Univ. of Virginia. Cardiovascular regulation: central control III (POSTER) The rostral ventrolateral medulla (RVLM) contains BS C1 adrenergic cells and non-CA neurons whose relative
SFN Poster of the Year 1999 Read More »
Exciting New Advances in Pain Research and Treatment Using Receptor Internalization Technologies – SFN 1999 Symposium
Symposium: “Exciting New Advances in Pain Research and Treatment Using Receptor Internalization Technologies” Society for Neuroscience (SFN) Symposium October 23-28, 1999 – Miami, Florida D.A. Thomas, NIDA-NIH (co-chair); R.G. Wiley, Vanderbilt University; W.J. Martin, UCSF; M.J. Iadorola, NIDCR-NIH; P. Mantyh, University of Minnesota; R.M. Caudle, University of Florida (co-chair) A press conference was held prior